RxDoctor Payments Data

Ebrahim Sajedi, MD

Internal Medicine · Montebello, CANPI 1154342269

Payments from drug & device makers

$4,463in general payments, 2019–2025

Across 249 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$602
  • Novo Nordisk$395
  • GSK$358
  • Bayer$328
  • Lilly USA, LLC$285
  • Regeneron Healthcare Solutions, Inc.$279
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,42499%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,463 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$469
Medicare patients
22
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$54,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$50,481
RybelsusSemaglutide28$35,483
Repatha SureclickEvolocumab42$34,792
JardianceEmpagliflozin42$32,903
Janumet XrSitagliptin Phos/Metformin Hcl47$28,717
LinzessLinaclotide38$27,950
TrulicityDulaglutide29$26,828
KerendiaFinerenone18$25,886
FarxigaDapagliflozin Propanediol35$25,461
TradjentaLinagliptin22$18,094
Jentadueto XrLinagliptin/Metformin Hcl31$15,930
MyrbetriqMirabegron21$15,396
JanuviaSitagliptin Phosphate11$14,475
Breo ElliptaFluticasone/Vilanterol28$11,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$395$90,25378 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto Xr$98$66,92795 claims
GSKTrelegy Ellipta, Breo Ellipta$358$61,588104 claims
MerckJanumet Xr, Januvia$186$43,19258 claims
AstraZenecaFarxiga, Breztri Aerosphere$235$35,22952 claims
AbbVieLinzess$234$27,95038 claims
Lilly USA, LLCTrulicity$285$26,82829 claims
BayerKerendia$328$25,88618 claims
PfizerEliquis$171$10,16012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Montebello

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →